Multiple Myeloma Treatment Denied by Insurance: How to Appeal

Multiple myeloma is a cancer of plasma cells in the bone marrow. While not curable with current treatments, the landscape has been transformed over the past decade — with proteasome inhibitors, IMiDs, anti-CD38 antibodies like daratumumab, and now CAR-T cell therapies offering patients years of remission and significantly improved survival. Insurance denials for these treatments are among the most challenging in all of oncology because of the cost and complexity involved. This guide explains the most common denial scenarios and how to fight back.

Common Multiple Myeloma Denial Scenarios

Daratumumab (Darzalex, Darzalex Faspro)

Daratumumab is a monoclonal antibody targeting CD38, used across multiple myeloma treatment lines. It is approved as:

• First-line therapy in combination with bortezomib/lenalidomide/dexamethasone (Dara-VRd) — the current standard-of-care induction regimen based on the PERSEUS trial
• Maintenance therapy post-transplant
• Second and later lines in multiple combinations

Insurers deny daratumumab by:

• Requiring step therapy through lenalidomide/dexamethasone or bortezomib/dexamethasone (Rd or Vd) before adding daratumumab, despite Dara-VRd being NCCN Category 1 first-line preferred
• Denying the subcutaneous formulation (Darzalex Faspro), which has equivalent efficacy and faster administration, in favor of the IV formulation
• Applying aggressive Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization timelines that delay cycle initiation

Proteasome Inhibitors (Bortezomib, Carfilzomib, Ixazomib)

Bortezomib (Velcade), carfilzomib (Kyprolis), and ixazomib (Ninlaro) are proteasome inhibitors used across multiple treatment lines. Carfilzomib is generally preferred over bortezomib for patients who cannot tolerate peripheral neuropathy (bortezomib's primary toxicity). Insurers deny:

• Carfilzomib, requiring bortezomib step therapy despite neuropathy contraindication
• Ixazomib (oral) over IV alternatives, restricting oral agents on specialty tier formulary

IMiDs: Lenalidomide, Pomalidomide, Thalidomide

Lenalidomide (Revlimid) and pomalidomide (Pomalyst) are immunomodulatory drugs central to myeloma treatment. Lenalidomide maintenance post-transplant is NCCN Category 1. Pomalidomide is used in later lines. Insurers deny:

• Lenalidomide maintenance by arguing it is "preventive" rather than therapeutic
• Pomalidomide citing formulary non-preferred tier, requiring step through lenalidomide (which may have lost efficacy)
• Oral drug coverage restrictions that apply different cost-sharing to oral vs. IV equivalents (the "oral chemo disparity" — addressed by some state laws)

Autologous Stem Cell Transplant (ASCT)

ASCT remains a standard consolidation therapy for transplant-eligible newly diagnosed multiple myeloma patients after induction therapy. NCCN Category 1 recommends ASCT for eligible patients. Insurers deny ASCT by:

• Age cutoffs more restrictive than clinical evidence supports (many 70+ year olds are transplant eligible)
• Performance status thresholds that override treating oncologist judgment
• Denying "tandem" ASCT for high-risk disease despite evidence in selected patients

CAR-T Cell Therapy: Carvykti (cilta-cel) and Abecma (ide-cel)

Ciltacabtagene autoleucel (Carvykti) and idecabtagene vicleucel (Abecma) are BCMA-targeted CAR-T cell therapies. FDA approvals:

• Abecma: For adults with relapsed/refractory multiple myeloma after 4+ prior lines
• Carvykti: Initially approved for 4+ prior lines; now has earlier-line approvals with continued label expansion

Insurers deny CAR-T for myeloma by:

• Counting prior treatment lines incorrectly to deny eligibility (misinterpreting what constitutes a "line")
• Requiring treatment at specific centers of excellence, then limiting access to distant, inconvenient centers
• Denying bridging therapy during CAR-T manufacturing (3-5 weeks)
• Using administrative delays in prior authorization that allow disease progression to the point of ineligibility

Belantamab Mafodotin and Other Novel Agents

Belantamab mafodotin (Blenrep), selinexor (Xpovio), elotuzumab (Empliciti), and isatuximab (Sarclisa) represent additional approved options in later-line myeloma. These agents are frequently denied as "investigational" or "non-preferred" despite FDA approval and NCCN listing.

Your Legal Rights

ACA essential health benefits: Myeloma treatment is covered with no annual or lifetime dollar limits.

External Independent Review: Complete Guide" class="auto-link">External review: For CAR-T and ASCT denials, independent external reviewers with hematologic oncology expertise regularly reverse insurer decisions. External review reversal rates for CAR-T in hematologic malignancy are among the highest in oncology appeals.

Expedited appeals: For patients with rapidly progressing multiple myeloma or those approaching CAR-T manufacturing timelines, expedited 72-hour review is appropriate and legally required upon request with clinical urgency documentation.

Oral chemotherapy parity laws: Several states require insurers to cover oral cancer drugs with the same cost-sharing as IV drugs. These laws protect access to lenalidomide, ixazomib, and pomalidomide.

Building Your Appeal

1. Pathology and bone marrow biopsy report: Confirming myeloma diagnosis, FISH cytogenetics, R-ISS staging
2. Prior treatment history: Documenting all prior lines of therapy with start/end dates and response
3. NCCN Multiple Myeloma Guidelines: Citing preferred regimen recommendations by disease status
4. FDA prescribing information: For Carvykti or Abecma confirming the approved indication and line
5. Letter of medical necessity: From board-certified hematologic oncologist, ideally at an academic center
6. ASCT eligibility documentation: For transplant denials, including HCT-CI score and oncologist assessment

Fight Back With ClaimBack

ClaimBack supports multiple myeloma patients in navigating complex insurance denials for CAR-T, ASCT, daratumumab, and other critical therapies. We help you build the evidence-driven appeal that your case deserves.

Start your appeal at ClaimBack

Multiple myeloma patients deserve access to the full armamentarium of approved treatments. Insurance denials are obstacles — not final decisions.

Related Reading

• How to Write an Insurance Appeal Letter
• Internal vs. External Insurance Appeals
• Common Reasons Insurance Claims Are Denied